PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30355923-0	2018	Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3beta Signaling Pathway in Human Hepatocellular Carcinoma.	erinacine S	0-9	glycogen synthase kinase 3 beta	Homo sapiens	124-133	
30355923-2	2018	The following study aims to investigate the role of erinacine in the opening of the mitochondrial permeability transition pore (MPTP) in hepatocellular carcinoma (HCC) through the PI3K/Akt/GSK-3beta signaling pathway and highlights the applicability of erinacine in HCC treatments.	erinacine S	52-61	glycogen synthase kinase 3 beta	Homo sapiens	189-198	
30355923-13	2018	In addition, Erinacine was found to decrease the mitochondrial membrane potential, expression of PI3K, Akt, GSK-3beta, CyclinD1, Vimentin, beta-catenin, and Bcl-2, cell proliferation, colony formation ability, migration, invasion, and xenograft tumor size, while E-cadherin, Bax, and caspase-9 expression, and cell apoptosis were elevated in a dose-dependent manner.	erinacine S	13-22	glycogen synthase kinase 3 beta	Homo sapiens	108-117	
30355923-16	2018	CONCLUSION: The results from the study demonstrated that erinacine induced MPTP opening, facilitates the release of cyt-C, and inhibited cell proliferation, migration, and invasion, while it promotes apoptosis by inactivating the PI3K/Akt/GSK-3beta signaling pathway, preventing the progression of HCC.	erinacine S	57-66	glycogen synthase kinase 3 beta	Homo sapiens	239-248